SCHEMBL9609331

SCHEMBL9609331

CCCCOC(=O)c1ccc(-c2nc(-c3ccccc3O)nc(-c3ccc(OC)cc3O)n2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.50
LMNA P02545 4/20 0.50
SMN1; SMN2 Q16637 4/20 0.50
KMT2A Q03164 4/20 0.50
ESR1 P03372 4/20 0.50
TSHR P16473 3/20 0.50
MEN1 O00255 3/20 0.50
HSD17B10 Q99714 3/20 0.50
CYP1A2 P05177 2/20 0.50
CYP2C19 P33261 2/20 0.50
MAPK1 P28482 2/20 0.50
USP2 O75604 1/20 0.50
TP53 P04637 1/20 0.50
HSP90AA1 P07900 1/20 0.50
XBP1 P17861 1/20 0.50
ALOX12 P18054 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
CYP2D6 P10635 1/20 0.50
NR1H2 P55055 1/20 0.50
RNASEL Q05823 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9609332 0.97 MAPT (0.48) MAPTLMNASMN1; SMN2KMT2AESR1
SCHEMBL12228396 0.95 LMNA (0.51) MAPTLMNASMN1; SMN2KMT2AESR1
SCHEMBL12228394 0.92 CNR2 (0.54) MAPTLMNASMN1; SMN2KMT2AESR1
SCHEMBL9608406 0.91 ESR1 (0.56) MAPTLMNASMN1; SMN2KMT2AESR1
SCHEMBL9609333 0.90 MAPT (0.55) MAPTLMNASMN1; SMN2KMT2AESR1
SCHEMBL12228393 0.89 MAPT (0.57) MAPTLMNASMN1; SMN2KMT2AESR1
SCHEMBL9608472 0.88 MAPT (0.48) MAPTLMNASMN1; SMN2KMT2AESR1
SCHEMBL15372573 0.88 MAPT (0.51) MAPTLMNASMN1; SMN2KMT2AESR1
SCHEMBL9608402 0.87 ALDH1A1 (0.56) MAPTLMNASMN1; SMN2ESR1TSHR
SCHEMBL9609298 0.87 LMNA (0.51) MAPTLMNASMN1; SMN2KMT2AESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8957140-B2 Triazine derivative, ultraviolet absorber, and resin composition FUJIFILM CORPORATION (JP) 2015-02-17 US disclosed
US-8748520-B2 Polycarbonate resin composition containing triazine compound and molded article using the same FUJIFILM CORPORATION (JP) 2014-06-10 US disclosed
US-8623990-B2 Polyester resin composition FUJIFILM CORPORATION (JP) 2014-01-07 US disclosed
US-20120301696-A1 POLYESTER RESIN COMPOSITION FUJIFILM CORPORATION (JP) 2012-11-29 US disclosed
US-20120136098-A1 NEW TRIAZINE DERIVATIVE, ULTRAVIOLET ABSORBER, AND RESIN COMPOSITION FUJIFILM CORPORATION (JP) 2012-05-31 US disclosed
US-20110077331-A1 POLYCARBONATE RESIN COMPOSITION CONTAINING TRIAZINE COMPOUND AND MOLDED ARTICLE USING THE SAME FUJIFILM CORPORATION (JP) 2011-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120136098-A1 NEW TRIAZINE DERIVATIVE, ULTRAVIOLET ABSORBER, AND RESIN COMPOSITION C1R, RPSA, H1-2 MAPT 1774/4885LMNA 1414/4885SMN1; SMN2 3721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.